COMMUNIQUÉ DE PRESSE publié le 17/01/2024 à 15:00, il y a 2 années 9 mois Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform Xenetic Biosciences, Inc. has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia to advance the development of its systemic DNase program, targeting neutrophil extracellular traps involved in cancer progression. The company believes that the data generated by its research and development collaborations are crucial for unlocking the potential of its DNase technology and driving a clinical path for its lead solid tumor indications. The agreement with UVA provides a significant addition to Xenetic's development capabilities and resources, accelerating development timelines. Dr. Allan Tsung, an internationally recognized surgical oncologist and scientist, will oversee the research conducted under the agreement. Xenetic is working towards its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. For more information, visit Xenetic Biosciences' website at www.xeneticbio.com. Xenetic Biosciences DNase Program Neutrophil Extracellular Traps Cancer Progression University Of Virginia
COMMUNIQUÉ DE PRESSE publié le 10/11/2023 à 14:35, il y a 2 années 11 mois Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
COMMUNIQUÉ DE PRESSE publié le 11/10/2023 à 15:05, il y a 3 années Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Publié le 04/11/2026 à 18:00, il y a 8 heures 22 minutes The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Publié le 04/11/2026 à 18:00, il y a 8 heures 22 minutes L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Publié le 04/11/2026 à 17:44, il y a 8 heures 38 minutes Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
Publié le 04/11/2026 à 23:10, il y a 3 heures 12 minutes Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Publié le 04/11/2026 à 23:00, il y a 3 heures 22 minutes Viemed Healthcare Announces Third Quarter 2026 Financial Results
Publié le 04/11/2026 à 22:15, il y a 4 heures 7 minutes Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Publié le 04/11/2026 à 22:05, il y a 4 heures 17 minutes Stabilis Solutions Announces Third Quarter 2026 Results
Publié le 05/11/2026 à 00:02, il y a 2 heures 20 minutes EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Publié le 04/11/2026 à 19:41, il y a 6 heures 41 minutes EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Publié le 04/11/2026 à 19:25, il y a 6 heures 57 minutes Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Publié le 04/11/2026 à 18:43, il y a 7 heures 39 minutes EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Publié le 04/11/2026 à 18:05, il y a 8 heures 17 minutes Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
